391 related articles for article (PubMed ID: 27517517)
1. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
3. Total glucosides of paeony (TGP) alleviates Sjogren's syndrome through inhibiting inflammatory responses in mice.
Li B; Liu G; Liu R; He S; Li X; Huang L; Wang Z; Li Y; Chen Y; Yin H; Fang W
Phytomedicine; 2020 Jun; 71():153203. PubMed ID: 32402913
[TBL] [Abstract][Full Text] [Related]
4. Total glucosides of paeony (TGP) alleviates constipation and intestinal inflammation in mice induced by Sjögren's syndrome.
Liu G; Wang Z; Li X; Liu R; Li B; Huang L; Chen Y; Zhang C; Zhang H; Li Y; Chen Y; Yin H; Fang W
J Ethnopharmacol; 2020 Oct; 260():113056. PubMed ID: 32525066
[TBL] [Abstract][Full Text] [Related]
5. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
6. [Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjögren syndrome].
Zhang HF; Hou P; Xiao WG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jul; 27(7):596-8. PubMed ID: 17717915
[TBL] [Abstract][Full Text] [Related]
7. Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjögren's syndrome: A systematic review.
Zhang A; Chen S; Lin R
Immun Inflamm Dis; 2023 Oct; 11(10):e1044. PubMed ID: 37904705
[TBL] [Abstract][Full Text] [Related]
8. Effects of total glucosides of paeony for delaying onset of Sjogren's syndrome: an animal study.
Li CL; He J; Li ZG; Zheng LW; Hua H
J Craniomaxillofac Surg; 2013 Oct; 41(7):610-5. PubMed ID: 23333492
[TBL] [Abstract][Full Text] [Related]
9. The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
Feng Z; Zhang BQ; Zhu YM; Yu BB; Fu L; Zhou LL; Zhou XP; Lu Y
Front Pharmacol; 2019; 10():550. PubMed ID: 31178729
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
11. Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Zhu Q; Qi X; Wu Y; Wang K
Int Urol Nephrol; 2016 Nov; 48(11):1873-1880. PubMed ID: 27342654
[TBL] [Abstract][Full Text] [Related]
12. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome?
Manthorpe R; Benoni C; Jacobsson L; Kirtava Z; Larsson A; Liedholm R; Nyhagen C; Tabery H; Theander E
Ann Rheum Dis; 2000 Jan; 59(1):54-60. PubMed ID: 10627428
[TBL] [Abstract][Full Text] [Related]
13. Total glucosides of paeony alleviates experimental Sjögren's syndrome through inhibiting NLRP3 inflammasome activation of submandibular gland cells.
Jiang T; Guo J; Wang Y; Wu H; Chen Y; Wang S; Zhang H; Long Q; Yao G
Clin Exp Rheumatol; 2023 Dec; 41(12):2502-2510. PubMed ID: 38149512
[TBL] [Abstract][Full Text] [Related]
14. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
[TBL] [Abstract][Full Text] [Related]
15. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
16. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.
Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC
Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433
[TBL] [Abstract][Full Text] [Related]
17. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
[TBL] [Abstract][Full Text] [Related]
18. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
19. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
20. Total glucosides of paeony (TGP) inhibits the production of inflammatory cytokines in oral lichen planus by suppressing the NF-κB signaling pathway.
Wang Y; Zhang H; Du G; Wang Y; Cao T; Luo Q; Chen J; Chen F; Tang G
Int Immunopharmacol; 2016 Jul; 36():67-72. PubMed ID: 27107800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
